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The cardiac L-type Ca2+ channel current (ICa) is an
important determinant of myocardial contractility. Its
regulation by neurotransmitters, hormones, and paracrine
factors contributes to the control of cardiac output to
meet the demands of the body. A large number of these
extracellular first messengers, acting on specific membrane
receptors in cardiac myocytes, regulate the activity of
adenylyl cyclase which in turn controls the intracellular
concentration of cAMP, the activity of the cAMP-
dependent protein kinase (PKA), and the degree of
phosphorylation and stimulation of L-type Ca2+ channels
(Hartzell, 1988; McDonald et al. 1994; Hove-Madsen et al.
1996; Striessnig, 1999). A typical example of such
regulation is the control of heart function by the
sympathetic and parasympathetic nervous systems, which
act via adrenoceptors and muscarinic receptors (Brodde &
Michel, 1999). In addition to the cAMP cascade, other
factors regulate heart function by acting primarily on the
cGMP cascade; these include atrial and brain natriuretic
peptides (de Bold et al. 1996) and nitric oxide (NO) (Paulus
& Shah, 1999; Shah & MacCarthy, 2000).
NO modulates cardiac contractility and rhythm in part
via its ability to control the amplitude of ICa (for reviews
see Fischmeister & Méry, 1996; Kelly et al. 1996; Kojda &
Kottenberg, 1999; Paulus & Shah, 1999; Shah &
MacCarthy, 2000). Classically, this regulation is mediated
through the generation of cGMP by NO-stimulated
soluble guanylyl cyclase activity. But, NO can also
regulate cardiac contraction (Chesnais et al. 1999;
Sandirasegarane & Diamond, 1999) or Ca2+ channel
activity (Campbell et al. 1996; Hu et al. 1997) through
cGMP-independent effects, so that the relative contribution
of cGMP-dependent or -independent mechanisms to the
overall effects of NO in the heart remains unresolved
(Shah & MacCarthy, 2000).
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1. The regulation of the L-type Ca2+ current (ICa) by intracellular cGMP was investigated in
human atrial myocytes using the whole-cell patch-clamp technique.
2. Intracellular application of 0.5 µM cGMP produced a strong stimulation of basal ICa (+64 ± 5 %,
n = 60), whereas a 10-fold higher cGMP concentration induced a 2-fold smaller increase
(+36 ± 8 %, n = 35).
3. The biphasic response of ICa to cGMP was not mimicked by the cGMP-dependent protein kinase
(PKG) activator 8-bromoguanosine 3fi,5fi cyclic monophosphate (8-bromo-cGMP, 0.5 or 5 µM),
and was not affected by the PKG inhibitor KT 5823 (100 nM).
4. In contrast, cGMP stimulation of ICa was abolished by intracellular perfusion with PKI (10 µM),
a selective inhibitor of the cAMP-dependent protein kinase (PKA).
5. Selective inhibition of the cGMP-inhibited phosphodiesterase (PDE3) by extracellular
cilostamide (100 nM) strongly enhanced basal ICa in control conditions (+78 ± 13 %, n = 7) but
had only a marginal effect in the presence of intracellular cGMP (+22 ± 7 % in addition to
0.5 µM cGMP, n = 11; +20 ± 22 % in addition to 5 µM cGMP, n = 7).
6. Application of erythro-9-[2-hydroxy-3-nonyl]adenine (EHNA, 30 µM), a selective inhibitor of
the cGMP-stimulated phosphodiesterase (PDE2), fully reversed the secondary inhibitory effect
of 5 µM cGMP on ICa (+99 ± 16 % stimulation, n = 7).
7. Altogether, these data indicate that intracellular cGMP regulates basal ICa in human atrial
myocytes in a similar manner to NO donors. The effect of cGMP involves modulation of the
cAMP level and PKA activity via opposite actions of the nucleotide on PDE2 and PDE3.
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Several studies in various animal species (reviewed in
Lohmann et al. 1991; Fischmeister & Méry, 1996) have
shown that exogenous cGMP can both stimulate or inhibit
ICa (Hartzell & Fischmeister, 1986; Levi et al. 1989; Ono &
Trautwein, 1991; Méry et al. 1991; Shirayama & Pappano,
1996; Han et al. 1998) and contractility (Nawrath, 1976;
Trautwein & Trube, 1976; Endoh & Yamashita, 1981;
Smith et al. 1991; Brady et al. 1993; Mohan et al. 1995;
Kojda et al. 1996). These opposite effects can be explained
by the presence of three different targets for cGMP with
different affinities for the nucleotide (Lohmann et al.
1991; Butt et al. 1992): (1) the cGMP-inhibited phospho-
diesterase (PDE3); (2) the cGMP-stimulated phospho-
diesterase (PDE2); (3) the cGMP-activated protein kinase
(PKG). The stimulatory effects on ICa or contractility
observed during modest activation of the NO–cGMP
pathway are best explained by cAMP elevation following
PDE3 inhibition (Ono & Trautwein, 1993; Méry et al.
1993; Wahler & Dollinger, 1995; Kojda et al. 1996). But,
the inhibitory effects of a strong activation of this
pathway can be attributed either to PDE2 stimulation (in
frog, Hartzell & Fischmeister, 1986; Méry et al. 1995) or
to PKG activation (in embryonic chick heart, Wahler et
al. 1990; Haddad et al. 1995; in adult mammalian heart,
Levi et al. 1989; Méry et al. 1991; Wahler & Dollinger,
1995; Sumii et al. 1995; Kojda et al. 1996). Surprisingly,
PKG was also reported to stimulate ICa in ventricular
myocytes from newborn (Kumar et al. 1997) and young
rabbit (Han et al. 1998). Altogether, these data indicate
that the relative contribution of the different cGMP
targets, as well as their final downstream modulation of
ICa and heart function, may vary depending on the species,
the developmental stage, and the region of the heart.
The variability in the results obtained in laboratory
animals makes it difficult to extrapolate to humans and
compelled us to directly assess the effects of NO and
cGMP in human heart. Patch-clamp experiments performed
in isolated human atrial myocytes demonstrated that NO
donors and cGMP also regulate ICa in this preparation. At
nanomolar concentrations, the NO donors SIN-1 and
SNAP produced a stimulation of basal ICa (Kirstein et al.
1995; Vandecasteele et al. 1998a). This effect was blocked
by intracellular methylene blue (Vandecasteele et al.
1998a), mimicked by PDE3 selective inhibitors (Kirstein
et al. 1995; Kajimoto et al. 1997) or by an intracellular
perfusion with cGMP (Rivet-Bastide et al. 1997).
Although the molecular mechanisms involved have not
been fully elucidated yet, these experiments suggested
that in human atrial myocytes low concentrations of NO
stimulated ICa via cGMP production and cGMP-inhibition
of PDE3 (Kirstein et al. 1995). Surprisingly, when used at
micromolar concentrations, the stimulatory effect of
SIN-1 on ICa was strongly attenuated, suggesting the
development of a secondary inhibitory effect at higher
concentrations (Kirstein et al. 1995). Whether this
secondary effect is also mediated by cGMP or results from
a direct effect of NO or some of its by-products (e.g.
resulting from the chemical reactions between NO,
superoxide, and peroxynitrite) on L-type Ca2+ channels
remains unknown.
In the present study, our aim was to dissect the mechanisms
involved in the regulation of ICa by intracellular cGMP in
human atrial myocytes. More specifically, we tried to
address two questions: (1) to what extent can changes in
intracellular cGMP mimic the bimodal regulation of ICa by
NO?; (2) what are the respective contributions of the
cGMP targets (PDE2, PDE3 and PKG) in the effect of
exogenous cGMP on ICa?
A preliminary report of some of these results has
appeared elsewhere (Vandecasteele et al. 1998b).
METHODS
Surgery
All protocols for obtaining human cardiac tissue were approved by
the ethics committee of our institution (GREBB, Hôpital de Bicêtre,
Université de Paris-Sud). Specimens of right atrial appendages were
obtained from 33 patients (aged 10–83 years) undergoing heart
surgery for congenital defects (n = 2), coronary artery diseases
(n = 25) or valve replacement (n = 6). All patients but five received a
pharmacological pre-treatment (Ca2+ channel blockers, digitalis,
b-adrenergic antagonists, diuretics, ACE inhibitors, NO donors
and/or anti-arrhythmic drugs). In addition, all patients received
sedatives, anaesthesia and antibiotics prior to surgery. But, we found
no obvious correlation between the Ca2+ current density or the effects
on ICa of the drugs tested here and the long-term therapy received (if
any) by the patient. Dissociation of the cells was realised immediately
after surgery.
Human atrial cell dissociation
Myocytes were isolated as described previously (Kirstein et al. 1995)
with some modifications. Briefly, quickly after excision, the tissue
was washed and cut in small pieces in a Ca2+-free Tyrode solution
supplemented with 30 mM 2,3-butanedione monoxime (BDM). Small
(~1 mm3) pieces of atria were then incubated in a BDM- and Ca2+-free
Tyrode solution containing 40 i.u. ml_1 collagenase, 15 i.u. ml_1
protease and 5 mg ml_1 BSA. After 30 min, this solution was
removed and replaced by fresh enzymatic solution containing only
collagenase (200 i.u. ml_1) for 10–20 min until a satisfactory cell yield
was obtained. All steps were carried out at 37 °C, with continuous
stirring at 200 r.p.m. and gassing with 95 % O2–5 % CO2. The cell
suspension was filtered, centrifuged (for 1 min at 600–700 r.p.m.)
and the pellet resuspended in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10 % fetal calf serum, non-essential
amino acids, 1 nM insulin and antibiotics (penicillin, 100 i.u. ml_1 and
streptomycin, 0.1 µg ml_1). For patch-clamp experiments, 20–100 µl
of this cell suspension was added to a control extracellular solution in
a Petri dish.
Electrophysiological experiments
The whole-cell configuration of the patch-clamp technique (Hamill et
al. 1981) was used to record the high-threshold L-type Ca2+ current
(ICa) on Ca
2+-tolerant human atrial myocytes. In the routine protocols
the cells were depolarised every 8 s from a holding potential of
_50 mV to 0 mV for 400 ms. This holding potential was chosen to
completely inactivate the fast Na+ current. K+ currents were blocked
by replacing all K+ ions with intracellular and extracellular Cs+.
Voltage-clamp protocols were generated by a challenger/09-VM
programmable function generator (Kinetic Software, Atlanta, GA,
USA). The cells were voltage clamped using a patch-clamp amplifier
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(model RK-400; Biologic, Claix, France). Currents were sampled at a
frequency of 10 kHz using a 12-bit analog–digital converter
(DT2827; Data Translation, Marlboro, MA, USA) connected to a PC-
compatible computer (386/33 System-pro; Compaq, Houston, TX,
USA). All experiments were done at room temperature (19–25 °C)
and the temperature varied by < 2 °C during the course of an
experiment.
Solutions
Control extracellular solution contained (mM): NaCl 107.1, Hepes 10,
CsCl 40, NaHCO3 4, NaH2PO4 0.8, CaCl2 1.8, MgCl2 1.8, D-glucose 5
and sodium pyruvate 5; pH 7.4 adjusted with NaOH. Patch
electrodes (0.8–1.5 MΩ) were filled with control GTP-free
intracellular solution that contained (mM): CsCl 119.8, EGTA (acid
form) 5, MgCl2 4, creatine phosphate disodium salt 5, Na2-ATP 3.1,
Hepes 10, and CaCl2 62 µM (pCa 8.5); pH 7.3 adjusted with CsOH. In
some experiments Na2-GTP (420 µM) was added to the GTP-free
intracellular solution, and the pH was readjusted. Control or drug-
containing solutions were applied to the exterior of the cell by placing
the cell at the opening of 250 µm inner diameter capillary tubing
flowing at a rate of ›10 µl min_1. Intracellular perfusion of the cell
with cyclic nucleotides or the PKA inhibitor PKI during whole-cell
recording was made possible by the use of a microcapillary inside the
patch-clamp pipette, as already described (Hartzell & Fischmeister,
1986). This capillary was connected to little tanks containing
intracellular solutions supplemented with cyclic nucleotides or PKI
at different concentrations. Application of a modest negative
pressure inside the patch electrode allowed flowing of the desired
solution to the tip of the pipette and inside the cell by passive
diffusion.
Materials
Collagenase type V and protease type XXIV, used for dissociation of
human atrial cells, and Na2-cGMP, Na2-8-bromo-cGMP, erythro-9-[2-
hydroxy-3-nonyl]adenine (EHNA), cAMP-dependent protein kinase
inhibitor (PKI, rabbit sequence) used in patch-clamp experiments
were from Sigma-Aldrich (L’Isle d’Abeau Chesnes, France). Cilostamide
was from Tocris Cookson (Bristol, UK) and KT 5823 was from
Calbiochem-France Biochem (Meudon, France). Cilostamide was
dissolved at 10 mM in ethanol. KT 5823 was dissolved at 100 mM in
DMSO. An equal amount of ethanol and/or DMSO corresponding to
the concentration present in the final dilutions was added to all other
solutions. All other drugs were dissolved in ionic aqueous solutions,
made fresh daily and kept at 4 °C until use.
Data analysis
The maximal amplitude of ICa was measured as the difference
between the peak inward current and the leak current (I400), which
was the current amplitude at the end of the 400 ms duration pulse
(Kirstein et al. 1995). Currents were not compensated for capacitive
and leak currents. Cell membrane capacitance and series resistances
were measured by exponential analysis of current responses to 1 mV
step changes in membrane potential. Membrane capacitance was
74.2 ± 21 pF (mean ± S.E.M.) and series resistance was 3.2 ± 0.2 MΩ
(n = 82). On-line analysis was performed by programming a PC-
compatible computer in PASCAL to determine peak and steady-state
current values for each depolarisation.
The results are expressed as means ± S.E.M. In each experimental
condition, the effects of the drugs tested on ICa are expressed as
percentage change with respect to the values of the current under
basal conditions, that is, in the absence of any hormonal stimulation.
The variations in ICa induced by the different drugs were tested for
statistical significance by Student’s t test. Statistically significant
differences between different conditions are indicated in the figures
as: *P < 0.05; **P < 0.01; ***P < 0.005.
RESULTS
Biphasic effect of cGMP on ICa
ICa was recorded in human atrial myocytes using the
whole-cell configuration of the patch-clamp technique
(Hamill et al. 1981). Basal ICa amplitude was measured
3–5 min after patch break to allow for equilibration
between intracellular and pipette solutions. Basal ICa
amplitude at a membrane potential of 0 mV was
241.0 ± 16.7 pA and ICa density, which represents the
ratio of ICa amplitude to membrane capacitance, was
3.2 ± 0.2 pA pF_1 (n = 82). As in our previous studies
(Kirstein et al. 1995; Rivet-Bastide et al. 1997;
Vandecasteele et al. 1998a), ICa densities showed a large
scatter between different patients and between
individual cells from the same patient, with no obvious
correlation with the diagnosis, sex, age or pretreatment of
the patients. Figure 1A illustrates a typical experiment
showing the effect of intracellular perfusion with cGMP
on the time course of ICa amplitude measured at 0 mV
from a holding potential of _50 mV. Two concentrations
of cGMP (0.5 and 5 µM) were successively dialysed into
the human atrial myocyte (see Methods). At the
beginning of the experiment, the cell was dialysed with
control intracellular (GTP-free) solution. After a stable
baseline was achieved, the control solution was changed
to a solution containing 0.5 µM cGMP (first arrow), which
produced about a 2-fold increase in ICa amplitude. This
effect was nearly abolished when the cGMP concentration
was increased to 5 µM (second arrow). Washout of cGMP
(third arrow) resulted in a rebound stimulation of ICa
before it returned slowly to the control level. As
summarised in Fig. 1B, on average 0.5 µM cGMP
stimulated ICa by 64 ± 5 % above control level (n = 60,
P < 0.001 vs. control) and subsequent application of 5 µM
cGMP resulted in an ›50 % attenuation of this effect
(36 ± 8 % above basal level, n = 35, P < 0.005 vs. control
and cGMP 0.5 µM). A lower concentration of cGMP
(0.15 µM) was tested in six other cells, but ICa increased in
only two of these cells, with an overall non-significant
effect of the nucleotide (23 ± 20 %, data not shown).
Application of a single high concentration of cGMP (5 or
50 µM) stimulated basal ICa by 76 ± 16 % (n = 5) and
53 ± 15 % (n = 5), respectively. But these effects were
only transient and the current amplitude returned to the
basal level after a few minutes.
As illustrated by the individual current traces shown in
Fig. 1A, the stimulatory effect of cGMP was not
accompanied by any significant modification in the
kinetics of ICa. This suggests that cGMP did not modify
the voltage dependence of the Ca2+ channel gating but to
examine this further, the effect of intracellular cGMP on
the ICa current–voltage (Fig. 2A) and inactivation
(Fig. 2B) relationships was investigated. The U-shape of
both curves for basal ICa (• in Fig. 2A and B), as well as
their respective positions on the voltage axis, are
characteristic of the high-threshold L-type Ca2+ current
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in this preparation (Kirstein et al. 1995). As shown,
0.5 µM cGMP increased ICa by a similar amount at every
membrane potential (Fig. 2A) and did not modify the
inactivation curve of the current (Fig. 2B). Thus, cGMP
modifies ICa in an essentially voltage-independent
manner.
So far, our results indicate that cGMP activates two
sequential mechanisms which affect ICa in an antagonistic
manner; a stimulatory mechanism activated at
concentrations below 0.5 µM and an inhibitory mechanism
activated at concentrations above 5 µM. It should be
noted that these cGMP concentrations do not necessarily
reflect the actual concentrations of the cyclic nucleotide
inside the cell. Indeed, access resistance to the cell and the
presence of cyclic nucleotide phosphodiesterases are likely
to lower drastically the intracellular cGMP concentration
effectively used by the cell. The above experiments were
performed in GTP-free intracellular solution, to limit the
extent of endogenous cGMP synthesis by the myocytes
(Rivet-Bastide et al. 1997) which might interfere with the
effects of exogenous cGMP introduced through the patch
pipette. Therefore, it was conceivable that the absence of
intracellular GTP might lead to a progressive reduction of
ICa due to a loss in a constitutive G protein activation of
adenylyl cyclase activity (Skeberdis et al. 1997;
Vandecasteele et al. 1998a), which could explain the
biphasic effect of cGMP. To examine this, we tested the
effect of cGMP in cells dialysed with GTP (420 µM). At
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Figure 1. Effect of intracellular application of
cGMP on basal ICa in human atrial myocytes
A, each symbol corresponds to a measure of ICa at
0 mV obtained every 8 s. The cell was first dialysed
with control GTP-free intracellular solution and
perfused with two concentrations of cGMP, first
0.5 µM and then 5 µM, at the time indicated by the
arrows. After the applications of 0.5 and 5 µM cGMP
the cell was dialysed with control intracellular
solution (washout). The individual current traces
shown in the upper part were obtained at the times
indicated by the corresponding letters in the graph
below. The horizontal line indicates the zero current
level. B, mean stimulatory effect of cGMP (0.5 µM, 5;
5 µM, 4), obtained using the same experimental
protocol as in A. The size of the bars indicates the
mean effects expressed as percentage increase over
basal ICa, and the lines the S.E.M., with the number of
experiments indicated above. *** P < 0.005,
statistically significant difference between both
conditions using Student’s t test.
Figure 2. Voltage dependence of the stimulatory
effect of cGMP on basal ICa in human atrial
myocytes
Current–voltage relationships (A) and inactivation
curves of ICa (B) in control condition (•) and in the
presence of 0.5 µM intracellular cGMP (A, 3; B, 1).
Inactivation curves were obtained using the double-
pulse protocol as indicated in the inset (see also
Methods).
this high concentration of GTP, application of 0.5 µM
cGMP (n = 19), followed by an application of either 5 µM
(n = 11) or 50 µM cGMP (n = 7), modified ICa by
+36 ± 4 % (at 0.5 µM, P < 0.001 vs. control), +26 ± 9 %
(at 5 µM, P < 0.05 vs. control) and _2 ± 6 % (at 50 µM, not
significant). Thus, the biphasic effect of cGMP was still
observed in the presence of GTP but addition of GTP
reduced about 2-fold the stimulatory effect on ICa of the
lowest cGMP concentration (0.5 µM; P < 0.005 vs. GTP
free). Moreover, in the presence of intracellular GTP, it
was necessary to increase the concentration of cGMP to
higher levels (50 µM instead of 5 µM) to activate the
secondary inhibitory mechanism. Thus, the presence of
intracellular GTP, most probably via activation of
endogenous cGMP synthesis (Rivet-Bastide et al. 1997),
attenuated the stimulatory effect of cGMP on ICa and
reduced the sensitivity of the inhibitory effect to the
nucleotide. For a better dissection of the mechanisms
involved in these two opposite effects, we returned to
GTP-free conditions for all subsequent experiments.
Role of cGMP-dependent protein kinase (PKG)
Our first goal in this study was to determine the
molecular mechanism by which cGMP stimulates ICa in
human atrial myocytes. Since PKG was shown to be
responsible for the stimulatory effect of cGMP on ICa in
rabbit ventricle (Han et al. 1998), we examined whether
8-bromo-cGMP, a potent activator of this enzyme (Butt et
al. 1992), could mimic the effect of cGMP. Figure 3A
shows a typical experiment in which a human atrial
myocyte was first dialysed with control (GTP-free)
intracellular solution, and, after a few minutes (first
arrow), was challenged with 5 µM 8-bromo-cGMP added
to the patch pipette. As shown, 8-bromo-cGMP had no
effect on basal ICa at this concentration. However, when
used at 100 µM, 8-bromo-cGMP clearly enhanced ICa, an
effect which amounted to ›50 % of the maximal
stimulation of the current obtained when the cell was
dialysed with 50 µM cAMP (fourth arrow). Figure 3B
summarises the results of several similar experiments in
which three concentrations of 8-bromo-cGMP were tested
(0.5, 5 and 100 µM). Whereas 0.5 and 5 µM of the cGMP
derivative had no effect on basal ICa (+2 ± 5 %, n = 3,
and _8 ± 11 %, n = 4, respectively), 100 µM increased the
current to 87 ± 18 % above basal level (n = 4, P < 0.05).
The above results indicate that 8-bromo-cGMP is 200-fold
less potent than cGMP in stimulating ICa. Since the cGMP-
derivative is more potent than the native nucleotide in
activating PKG (Butt et al. 1992), these results argue
against an involvement of this enzyme in the stimulatory
effect of cGMP on ICa. However, to examine this
hypothesis further, we tested the effect of KT 5823, a
highly selective (Komalavila & Lincoln, 1996) and
commonly used PKG inhibitor (Wahler & Dollinger, 1995;
Kumar et al. 1997). KT 5823 was used at 100 nM, a
concentration which significantly reduced the inhibitory
effect of NO donors on ICa in guinea-pig (Wahler &
Dollinger, 1995) and rat ventricular myocytes (Abi-
Gerges et al. 2001) but which is unlikely to inhibit PKA
(Kase et al. 1987). As shown in Fig. 4, extracellular
application of KT 5823 on human atrial myocytes did not
modify the stimulatory effect of an intracellular
application of either 0.5 µM cGMP (Fig. 4A) or 100 µM
8-bromo-cGMP (Fig. 4B) on ICa. As summarised in Fig. 4C,
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Figure 3. Effect of intracellular 8-bromo-cGMP
and cAMP on basal ICa in human atrial myocytes
A, the cell was superfused with control extracellular
solution throughout the experiment. Each symbol
corresponds to a measure of ICa at 0 mV obtained
every 8 s. At the beginning of the experiment, the cell
was intracellularly dialysed with control GTP-free
intracellular solution. The same solution containing
5 µM 8-bromo-cGMP was allowed to diffuse into the
cytoplasm, without any notable effect on ICa (first
arrow). In contrast, 100 µM of the cGMP derivative
(second arrow) roughly doubled the current
amplitude. After washout of 8-bromo-cGMP (third
arrow), a maximal stimulation of ICa was obtained by
perfusing the myocyte with 50 µM cAMP (last arrow).
B, summary of the effects of 8-bromo-cGMP (0.5, 5
and 100 µM) on ICa in human atrial myocytes. The size
of the bars indicates the mean effects expressed as
percentage variation relative to basal ICa, and the
lines the S.E.M., with the number of experiments
indicated above. * P < 0.05, statistically significant
difference from control ICa amplitude using Student’s
t test.
0.5 µM cGMP produced a 72 ± 15 % (n = 6) and 92 ± 24 %
(n = 6) stimulation of basal ICa in the absence or presence,
respectively, of KT 5823. Similarly, in three cells,
intracellular perfusion with 100 µM 8-bromo-cGMP
induced a 102 ± 21 % increase in basal ICa, and this effect
remained unchanged after a subsequent application of
100 nM KT 5823 (92 ± 15 %, Fig. 4C). Altogether, these
results exclude the possibility that PKG plays a
determinant role in the stimulatory effect of cGMP on ICa.
Role of cAMP-dependent protein kinase (PKA)
To examine the participation of PKA in the stimulatory
effect of cGMP on basal ICa in human atrial myocytes, we
performed experiments in which cGMP stimulation was
followed by intracellular perfusion with PKI, a highly
selective peptide inhibitor of PKA (Walsh et al. 1990). In
four cells, intracellular perfusion with 0.5 µM cGMP
increased ICa by 30 ± 4 % above the control value. After
stabilisation of ICa amplitude, intracellular perfusion was
switched to a solution containing 10 µM PKI added to the
cGMP (0.5 µM)-containing solution. This quickly resulted
in abolition of the cGMP stimulation of ICa and in a
decrease in the calcium current amplitude below the
initial baseline (54 ± 6 % below control value, see also
Skeberdis et al. 1997). Thus, the stimulatory effect of cGMP
on ICa is likely to be mediated by activation of PKA.
Role of cGMP-inhibited phosphodiesterase (PDE3)
One possible way by which cGMP could stimulate ICa in a
PKA-dependent manner is through an increase in cAMP
concentration due to inhibition of the cGMP-inhibited
phosphodiesterase (PDE3). PDE3 was shown to regulate
basal ICa in human atrial myocytes (Kirstein et al. 1995)
and to be implicated in the stimulatory effect of cGMP on
the isoprenaline-stimulated ICa in guinea-pig ventricular
myocytes (Ono & Trautwein, 1991; Shirayama & Pappano,
1996). To examine a possible role of PDE3 in the effect of
cGMP, we compared the effect of cGMP with that of
cilostamide, a selective PDE3 inhibitor (Stoclet et al. 1995).
As shown in Fig. 5, extracellular application of cilostamide
(100 nM; Fig. 5A) and intracellular dialysis with cGMP
(0.5 µM; Fig. 5B) produced comparable stimulatory
effects on ICa. Moreover, when cilostamide was added as
well as cGMP, it had only a marginal additional effect on
ICa (Fig. 5B). The summary data of Fig. 5C allow for a
comparison of the mean effects on basal ICa of cilostamide
(100 nM), cGMP (0.5 µM) and of both compounds applied
together. As shown, cilostamide and cGMP used alone
produced very similar stimulatory effects on ICa,
78 ± 13 % (n = 7) and 64 ± 8 % (n = 11), respectively.
When cilostamide was added to cGMP, the effect of the
nucleotide was increased by 22 ± 7 % (n = 11, P < 0.05,
paired t test). These results indicate that the stimulatory
effect of cGMP was mimicked by a selective PDE3
inhibitor, and the effect of PDE3 inhibition was greatly
reduced in the presence of cGMP. Therefore, partial PDE3
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Figure 4. Role of cGMP-dependent protein kinase
(PKG) in the stimulatory effect of cGMP on ICa in
human atrial myocytes
A and B, two representative experiments showing the
absence of effect of PKG inhibition by KT 5823
(100 nM) on ICa stimulated by cGMP (0.5 µM; A) and
8-bromo-cGMP (100 µM; B), in human atrial
myocytes. Each symbol corresponds to a measure of
ICa at 0 mV obtained every 8 s. In both experiments
the cell was initially perfused with the usual GTP-
free control intracellular solution, then dialysed with
cGMP or 8-bromo-cGMP. As can be seen, both cyclic
nucleotides clearly enhanced ICa. Superfusion of the
cell with 100 nM KT 5823 in addition to cGMP or
8-bromo-cGMP failed to modify the amplitude of ICa.
During the interruption of the curve in A,
current–voltage (I–V) relationships were obtained,
like those illustrated in Fig. 2A. Then the routine
stimulation protocol was applied again. C, comparison
of the mean effect of cGMP (0.5 µM, 5) and 8-bromo-
cGMP (100 µM, 4) in the absence and presence of KT
5823 (100 nM). The size of the bars indicates the mean
effects expressed as percentage increase over basal ICa,
and the lines the S.E.M., with the number of
experiments indicated above.
inhibition is likely to be responsible for the cGMP-induced
stimulation of ICa in human atrial myocytes.
Role of cGMP-stimulated phosphodiesterase (PDE2)
As shown above, the stimulatory effect of cGMP on ICa is
reduced when the concentration of cGMP is increased.
This suggests the development of a secondary inhibitory
mechanism at higher cGMP concentrations. As stated in
the Introduction, two possible mechanisms could account
for a cGMP-dependent inhibition of ICa: activation of
PKG or activation of the cGMP-stimulated phospho-
diesterase (PDE2). In order to differentiate between these
two possibilities, we tested the effects of KT 5823, the
PKG inhibitor, and EHNA, a selective PDE2 inhibitor
(Méry et al. 1995; Rivet-Bastide et al. 1997), for their
ability to reverse the effect of 5 µM cGMP on ICa. In the
experiment shown in Fig. 6A, a human atrial myocyte
was first dialysed with 0.5 µM cGMP, resulting in
approximately 60 % stimulation of basal ICa. This effect
was strongly reduced when the concentration of cGMP
was increased to 5 µM. During the decrease in ICa, the cell
was successively exposed to KT 5823 (100 nM), cilostamide
(100 nM) and EHNA (30 µM). As shown, KT 5823 did not
antagonise the inhibitory effect of cGMP, and cilostamide
induced only a 15 % increase in ICa. By contrast, application
of EHNA induced a strong and reversible stimulation of
ICa which recovered to the amplitude obtained in the
presence of 0.5 µM cGMP. The results of several similar
experiments are summarised in Fig. 6B. In 14 cells, 0.5 µM
cGMP increased ICa by 70 ± 10 % and a subsequent
increase in cGMP concentration to 5 µM reduced this
stimulation to 25 ± 11 % above control level (P < 0.01 vs.
0.5 µM cGMP). In seven individual cells, extracellular
application of either KT 5823 (100 nM) or cilostamide
(100 nM) in the continuous presence of intracellular cGMP
(5 µM) had no significant effect on the current amplitude
(+17 ± 14 %, P = 0.73, and +20 ± 22 %, P = 0.83,
respectively). This indicates that activation of PKG does
not account for the inhibitory effect of cGMP on ICa and
that PDE3 is already fully inhibited at 5 µM cGMP.
Exposure of the cells to EHNA (30 µM) induced a strong
stimulation of ICa, to 99 ± 16 % above the control level
(n = 7, P < 0.005 vs. 5 µM cGMP), an effect which was
similar to that seen with 0.5 µM cGMP. These results
demonstrate that the inhibitory effect of cGMP on ICa in
human atrial myocytes involves an activation of PDE2.
DISCUSSION
In the present study, we examined the effects of cGMP on
the L-type Ca2+ current (ICa) in human atrial myocytes.
Several main conclusions can be drawn from our
experiments: (1) cGMP activates two sequential mechanisms
which affect ICa in an antagonistic manner, a stimulatory
mechanism activated at concentrations below 0.5 µM and
an inhibitory mechanism activated at concentrations above
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Figure 5. Effect of PDE3 inhibition by
cilostamide on basal and cGMP-stimulated ICa in
human atrial myocytes
A and B, each symbol corresponds to a measure of ICa
at 0 mV obtained every 8 s. Both experiments were
carried out using a GTP-free intracellular solution.
A, after a few minutes during which the cell was
superfused with control extracellular solution,
extracellular application of 100 nM cilostamide during
the period indicated by the horizontal line produced
an ›60 % increase of ICa above control level. B, the
same extracellular application of 100 nM cilostamide
had only a modest effect when ICa had been
previously increased by intracellular perfusion with
0.5 µM cGMP (first arrow). The second arrow indicates
the washout of intracellular cGMP. C, summary of the
effect of cilostamide (100 nM, 5), cGMP (0.5 µM, %)
and the combination of both (4) on basal ICa. The size
of the bars indicates the mean effects expressed as
percentage increase over basal ICa, and the lines the
S.E.M., with the number of experiments indicated
above. * P < 0.05, statistically significant differences
using Student’s t test.
5 µM; (2) the regulation of ICa by cGMP is not accompanied
by any modification in the voltage dependence of the
Ca2+ current; (3) PKG does not seem to play a major role
in either of these two opposite mechanisms; (4) the
stimulatory effect of cGMP is due to activation of PKA
resulting from a cGMP-dependent inhibition of PDE3; (5)
the inhibitory effect is due to a reduction in PKA via
cGMP-dependent stimulation of PDE2. We conclude that
cGMP regulates ICa in human atrial myocytes by controlling
the intracellular concentration of cAMP through opposing
actions on PDE3 and PDE2.
This study follows up and confirms earlier studies from
our laboratory on the regulation of basal ICa by NO donors
(Kirstein et al. 1995; Vandecasteele et al. 1998a) and by
PDE2 in human atrial myocytes (Rivet-Bastide et al.
1997). In particular, we found that SIN-1 stimulates ICa in
the nanomolar concentration range, an effect which is
reduced when the concentration of the NO donor is
increased in the micromolar range (Kirstein et al. 1995).
The present experiments reveal that intracellular perfusion
with cGMP, the second messenger of NO, produces very
similar effects on ICa in human atrial myocytes.
Over the last 15 years, numerous studies have reported
opposite and contradictory effects of intracellular cGMP
on ICa in different cardiac preparations (for review, see
Lohmann et al. 1991; Fischmeister & Méry, 1996).
Although it is still difficult to draw a clear picture of the
effects of the nucleotide on heart function, all these
studies have contributed to our understanding that the
cGMP signalling pathways are intimately linked to those
of cAMP and involve three main enzymes, namely PDE2,
PDE3 and PKG (Hove-Madsen et al. 1996). Thus, it is now
accepted that cGMP will produce different effects
depending on: (1) the presence and relative activities of
these three enzymes; (2) their respective location inside
the cell; (3) their respective affinities for cGMP; (4) whether
adenylyl and/or guanylyl cyclases are constitutively
active in the cells under study; (5) the concentration of
cGMP used; (6) whether native cGMP or a cGMP analogue
is used; (7) whether the effect of cGMP on ICa is examined
under basal conditions or after the current has been
enhanced by activation of the cAMP cascade. While the
last three conditions are determined by the experimental
conditions, the others are essentially determined by the
animal species, the cardiac tissue, the developmental
stage, and the pathophysiological condition of the
preparation. For instance, cGMP stimulates basal ICa via
PKG in ventricular myocytes isolated from neonatal
(Kumar et al. 1997) and young rabbit hearts (Han et al.
1998), but has no effect on basal ICa in adult rabbit heart
(Kumar et al. 1997) due to a lower expression of PKG in
adult heart (Kumar et al. 1999). Isoprenaline-stimulated
ICa is inhibited by cGMP in rat (Méry et al. 1991; Sumii &
Sperelakis, 1995) and guinea-pig ventricular myocytes
via activation of PKG (Levi et al. 1989), while cGMP
inhibits the current via PDE2 activation in frog
ventricular myocytes (Hartzell & Fischmeister, 1986).
Since PKG has been shown to mediate the stimulatory
effect of cGMP on basal ICa in rabbit ventricular myocytes
(Kumar et al. 1997; Han et al. 1998), we first examined
whether PKG contributed to the stimulatory effect of
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Figure 6. Contribution of PKG, PDE3 and PDE2
to the inhibitory effect of cGMP on ICa in human
atrial myocytes
A, each symbol corresponds to a measure of ICa at
0 mV obtained every 8 s. The cell was first dialysed
with intracellular GTP-free solution. Intracellular
dialysis with 0.5 µM cGMP (first arrow) resulted in the
usual stimulation of ICa, and switching to 5 µM cGMP
(second arrow) partially reversed this stimulatory
effect. Superfusion of the cell with KT 5823 (100 nM)
or cilostamide (100 nM) had little or no effect on ICa,
whereas EHNA (30 µM) restored the amplitude of the
current observed in the presence of 0.5 µM cGMP.
B, summary of several experiments similar to those
shown in A. The effect of cGMP (0.5 µM, 5; 5 µM, 4)
on ICa is shown in the absence or presence of KT 5823
(100 nM), cilostamide (100 nM) or EHNA (30 µM). The
size of the bars indicates the mean effects expressed
as percentage increase over basal ICa, and the lines the
S.E.M., with the number of experiments indicated
above. ** P < 0.01, *** P < 0.005, statistically
significant differences using Student’s t test.
cGMP in human atrial myocytes. However, the negative
results obtained with 8-bromo-cGMP or KT 5823 forced
us to reject this hypothesis. In the case of 8-bromo-cGMP,
a stimulation of ICa was observed only at 100 µM, which is
a 200-fold higher concentration than necessary when
using native cGMP. Nevertheless, since 8-bromo-cGMP is
10-fold more potent than cGMP in activating PKG (Butt
et al. 1992), we suspect that the stimulation of ICa seen at
such a high concentration was not due to PKG but rather
to PKA activation. Indeed, 8-bromo-cGMP was shown to
activate PKA with a Kd of 12 µM (Butt et al. 1992). In
addition, 8-bromo-cGMP was shown to inhibit PDE3 with
a Ki of 8 µM (Butt et al. 1992) which may lead to cAMP
accumulation and activation of PKA (see below).
The stimulatory effect of cGMP on ICa in human atrial
myocytes clearly involved activation of a cAMP-
dependent phosphorylation process. Indeed, PKA
inhibition with PKI completely abolished the stimulatory
effect of cGMP. The PKA-mediated activation of ICa is
most probably due to the phosphorylation of a subunit on
the L-type Ca2+ channel (Gao et al. 1997; Bünemann et al.
1999; Striessnig, 1999). Interestingly, PKI not only
antagonised the cGMP effect but also decreased basal ICa
amplitude (see also Skeberdis et al. 1997). This indicates
that, in human atrial myocytes, a constitutive PKA
activity persists in the absence of any cAMP elevating
stimulus and contributes to the basal amplitude of ICa.
This constitutive PKA activity is most probably due to a
substantial basal cAMP synthesis resulting from a
constitutive activity of adenylyl cyclase. Indeed,
acetylcholine decreases (Vandecasteele et al. 1998a) and
phosphodiesterase inhibitors increase (Kirstein et al. 1995;
Rivet-Bastide et al. 1997) basal ICa in this preparation.
To gain further insight into the mechanism by which
cGMP enhances PKA activity, we tested the hypothesis
that cGMP leads to cAMP elevation though an inhibition
of PDE3. Our reasoning was that cGMP inhibits PDE3 in
a submicromolar range of concentrations (Butt et al.1992),
and also that PDE3 inhibition with milrinone mimicked
the stimulatory effect of a low concentration of NO
donors on ICa in human atrial myocytes (Kirstein et al.
1995; Vandecasteele et al. 1998a). We found indeed that
cilostamide, a highly selective PDE3 inhibitor (Stoclet et
al. 1995), mimicked the stimulatory effect of 0.5 µM
cGMP on ICa and induced little additional effect in the
presence of the cyclic nucleotide. Thus we conclude that
cGMP stimulation of ICa in human atrium is due to
inhibition of PDE3.
Surprisingly, increasing the concentration of cGMP from
0.5 to 5 µM reduced the stimulatory effect seen at the
lowest concentration. This dual effect of cGMP was
observed whether GTP was present or not in the pipette
solution, refuting the hypothesis that a progressive
reduction in the spontaneous activity of Gs proteins and
adenylyl cyclase contributed to this phenomenon. But
when GTP was present, the stimulatory effect of 0.5 µM
cGMP on ICa was reduced approximately 2-fold, possibly
because in this situation exogenous cGMP has to compete
with endogenous cGMP production which is stimulated
by the presence of GTP (Rivet-Bastide et al. 1997).
The attenuation of the stimulatory response of ICa to
cGMP when the concentration of the nucleotide is
increased suggests the existence of a secondary inhibitory
mechanism with a lower sensitivity to cGMP than PDE3.
Two possible candidates for such an inhibitory mechanism
exist: (i) cGMP activation of PDE2 and (ii) cGMP activation
of PKG (Lohmann et al. 1991; Fischmeister & Méry,
1996). Whereas PKG inhibition by KT 5823 was
ineffective, PDE2 blockade by EHNA, a selective PDE2
inhibitor (Méry et al. 1995), fully reversed the inhibitory
effect of 5 µM cGMP. Thus, PDE2 rather than PKG was
responsible for the secondary inhibitory effect of cGMP
on ICa in human atrial myocytes. In this respect, human
atrial myocytes behave like frog ventricular myocytes
where PDE2 activation is responsible for cGMP inhibition
of pre-stimulated ICa (Hartzell & Fischmeister, 1986;
Méry et al. 1995). This result was somewhat surprising
because most previous electrophysiological studies
suggested a predominant role of PKG in NO donor and/or
cGMP inhibition of ICa in mammalian species (Thakkar et
al. 1988; Levi et al. 1989; Wahler et al. 1990; Méry et al.
1991; Wahler & Dollinger, 1995; for review, see Lohmann
et al. 1991). However, all these studies in mammalian
heart were performed in ventricular tissues, so the
possibility exists that atrial tissue differs from ventricular
tissue in the amount of the respective cGMP target
enzymes, their localisation within the cell and/or their
coupling to L-type Ca2+ channels. The resemblance in the
action of cGMP on ICa in human atrial and frog ventricular
myocytes would support this hypothesis, since these two
preparations share a number of similarities both on
ultrastructural and functional grounds (see e.g. Morad &
Cleeman, 1987).
Our demonstration that cGMP, like NO donors (Kirstein
et al. 1995), exerts two opposite effects on ICa in human
atrium may have pathophysiological relevance. Indeed,
human cardiomyocytes possess a Ca2+-dependent NO
synthase (NOS) subtype which is constitutively expressed
in endothelium (NOS3) (Wei et al. 1996), and are at
reasonable diffusion distances from other NOS sources
located in endothelial (NOS3) and neuronal cells (NOS1).
Therefore, NO is likely to modulate myocardial
contractility under physiological conditions (Shah &
MacCarthy, 2000). Moreover, exogenous application of
NO by NO donors modulates cardiac contractility (Kojda
& Kottenberg, 1999; Paulus & Shah, 1999; Shah &
MacCarthy, 2000), including in human atrium (Flesch et
al. 1997). Finally, myocardial cells are exposed to high
concentrations of NO upon induction of the Ca2+-
independent NOS (NOS2), which occurs in several
pathological states, such as sepsis (Schulz et al. 1992;
Thoenes et al. 1996), heart failure (De Belder et al. 1993;
Haywood et al. 1996; Vejlstrup et al. 1998) and cardiac
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allograft rejection (Yang et al. 1994; Paulus et al. 1997).
Although it is likely that the cGMP-dependent
alterations in ICa observed in this study contribute to the
alterations in myocardial function in these pathological
situations (but see Abi-Gerges et al. 1999), a number of
other mechanisms may also be relevant, including a
cGMP-dependent reduction of myofilament response to
Ca2+ (Shah et al. 1994; Shah & MacCarthy, 2000), cGMP-
independent effects on L-type Ca2+ channels (Campbell et
al. 1996; Hu et al. 1997), ryanodine receptors (Xu et al.
1998), creatine kinase (Gross et al. 1996) or mitochondrial
respiration (Wolin et al. 1997) and modulation by NO of
cardiovascular reflexes (Zanzinger, 1999). Additional
studies are needed to evaluate the respective contribution
of each of these mechanisms to the overall cardiac
response to NO.
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